Company Snapshot
Veraxa Biotech Holding AG investment report
Start with VRXA at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.
Veraxa Biotech Holding AG
NASDAQ:VRXABiotechnology
-$1.60 today
- Market cap
- $145.65M
- Beta
- -0.40
Volume 0.10M
Average 0.02M
Intrinsic Value
VRXA Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Veraxa Biotech Holding AG
NASDAQ:VRXA
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Monitor VRXA
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price alerts
Get notified when VRXA drops below your target
Current price baseline
$1.03
Current price $1.03
Sign in to activate price alerts.
Price History
How has VRXA traded over time?
Review how the market has priced Veraxa Biotech Holding AG over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.
Price history
Dividend-adjusted closing price
Period change
-91.59%
Period high
$24.79
Period low
$0.95
Latest
$1.03
Investment Notes
Capture the investment case
Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.
My notes
Journal entries for VRXA
Sign in to keep notes
Keep your research and decisions in your personal journal.
Fundamental Analysis
Test company quality against your thesis
Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
VRXA Earnings Waterfall · TTM
NASDAQ:VRXA · Revenue to Net Income
No earnings data available.
Revenue Mix
See which products and regions drive the business
Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.
Revenue by segment
Where VRXA earns its revenue, as reported in company filings
This company does not report revenue segments.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
No balance sheet data available.
Cash Generation
Test whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
No cash flow data available.
Quality Snapshot
Check the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
Management
Judge how Veraxa Biotech Holding AG allocates capital
Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.
Capital Efficiency
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Dividend Record
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
—
Annual Div/Share
$0.00
Payout Ratio
—
Frequency
—
Shareholder Yield
—
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is not available.
Owner Returns
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
No shareholder return data available.
Insider Activity
Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$125,332.66
Sells
0
$0.00
Net Transaction Value
+$125,332.66
Net buying
Most Active
Gruninger Marc
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 28, 26Oct 28, 2026 | Gruninger Marc Direct | Buy | $9.1K$9,133.00 |
| Oct 27, 26Oct 27, 2026 | Gruninger Marc Direct | Buy | $849.7$849.66 |
| Oct 20, 26Oct 20, 2026 | Ziegler Christoph Samuel Direct | Buy | $32.7K$32,700.00 |
| Aug 27, 26Aug 27, 2026 | Baumann Oliver Rolf Indirect | Buy | $75K$75,000.00 |
| Aug 27, 26Aug 27, 2026 | Antz Christoph Rudiger Direct | Buy | $7.7K$7,650.00 |
Summary
Insiders reported 5 buys worth $125,332.66 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $125,332.66. Gruninger Marc was the most active insider with 2 transactions.
Leadership
Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Christoph Antz | Co-Founder, Lead Director & CEO | — | 64 | — | — |
Christoph Erkel | Chief Scientific Officer | — | 49 | — | — |
Heinz Schwer | Chief Business Officer | — | 58 | — | — |
Carl von Halem | Principal Financial Officer & Principal Accounting Officer | — | — | 0 | <0.01% |
Raju Willener | Chief Financial Officer | — | — | — | — |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 10, 2026.
Alternatives to VRXA
Compare Veraxa Biotech Holding AG with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
No competitor data available.
Analysts
What Wall Street expects from VRXA
Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.
Analyst Targets
See where analysts expect VRXA to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for VRXA.
Analyst Ratings
How analysts rate VRXA today
See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
No analyst ratings available.
Company Overview
Understand how Veraxa Biotech Holding AG makes money
Ground the financial evidence in the company profile, business description, and key facts.
Key Information
Stock Analysis
Turn the VRXA report into your next decision
Record your conclusion, evidence, and concerns in a structured analysis workspace.
Investment analysis
Turn VRXA research into a decision
Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.
Sign in on the next page to save a private analysis.
Start analysisFAQ
Common questions about VRXA
Resolve the remaining questions before moving into the detailed workspaces.
Explore
Continue your research
Open the detailed valuation, financial, health, and management workspaces.
Continue the stock analysis
Jump to another research area for this company.